Pharmaceutical Regulatory System for Vaccine Approval: A Comparative Study of Indian, Australian and Japanese Systems
DOI:
https://doi.org/10.52783/jns.v14.2747Keywords:
Vaccine Regulation, Regulatory Frameworks, Clinical Trials, International Harmonization, Pharmacovigilance, Quality Control Standards, Regulatory ConvergenceAbstract
Vaccine regulation is significantly different among Asia-Pacific countries, with each country taking on a unique approach based on its capabilities and needs. This study explores the regulatory frameworks for vaccine development and approval in India, Australia, and Japan, focusing on their methodologies and potential for international harmonization. Four key aspects will be analyzed: approval processes, clinical trial requirements, quality control standards, and post-marketing surveillance systems, especially GMP standards and pharmacovigilance requirements under the impact of the COVID-19 pandemic.The results present clear, distinguishing characteristics of the different countries under study: India developed a pragmatic system focused on global manufacturing capabilities, while Australia maintained robust processes with high international harmonization. In Japan, although there exists a strict approval pathway, international cooperation increased over time. Regulatory changes were catalyzed by the COVID-19 pandemic, especially in expedited review processes and international collaboration.Country-specific adjustments to convergence in standards continue to be called for. Major cited challenges include unevenness in terms of resource distribution, differences in technological capabilities and issues concerning coordination among nations. Vaccine regulation may well find its shape in reaction to innovation with digital technology, advanced analytics, and stronger international cooperation and is likely to demand careful attention to local conditions.This gives valuable insights into the regulation of vaccines by the authorities, pharmaceutical firms, and policymakers, thus working in harmony to strengthen health security. In essence, these give scope for both opportunities presented by digital transformation and international cooperation, with emphasis on local contextualization for implementation.
Downloads
Metrics
References
Moradpour J, Chit A, Besada-Lombana S, Grootendorst P. Overview of the global vaccine ecosystem. Expert Rev Vaccines. 2023 Jan-Dec;22(1):749-763. doi: 10.1080/14760584.2023.2250433. PMID: 37608523.
Plitnick LM. Global regulatory guidelines for vaccines. InNonclinical development of novel biologics, biosimilars, vaccines and specialty biologics 2013 Jan 1 (pp. 225-241). Academic Press.
Baylor NW. Role of the national regulatory authority for vaccines. International Journal of Health Governance. 2017 Sep 4;22(3):128-37.
Nachlis H, Thomson K. Emergency Regulatory Procedures, Pharmaceutical Regulatory Politics, and the Political Economy of Vaccine Regulation in the COVID-19 Pandemic. J Health Polit Policy Law. 2024 Feb 1;49(1):73-98. doi: 10.1215/03616878-10910278. PMID: 37522337.
Lacey S, Mitchell AD. Regulatory Cooperation for Vaccines: The Asia-Pacific and Beyond. Asian International Studies Review. 2023 Apr 26;24(1):74-102.
Shi J, Chen X, Hu H, Ung COL. Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities. Front Public Health. 2023 May 4;11:1172557. doi: 10.3389/fpubh.2023.1172557. PMID: 37213606; PMCID: PMC10192700.
Salalli R, Dange JR, Dhiman S, Sharma T. Vaccines development in India: advances, regulation, and challenges. Clin Exp Vaccine Res. 2023 Jul;12(3):193-208. doi: 10.7774/cevr.2023.12.3.193. Epub 2023 Jul 31. PMID: 37599804; PMCID: PMC10435768.
Sakurai A, Kanzaki S, Honda F. Japanese Pharmaceutical Regulations of Engineered Viral Vectors for Medical Use Compared With Those in the United States and the European Union. Clin Pharmacol Ther. 2023 May;113(5):960-962. doi: 10.1002/cpt.2788. Epub 2022 Nov 20. PMID: 36404404.
Lacey S, Mitchell AD. Regulatory Cooperation in Vaccines in Asia-Pacific Region. Available at SSRN 4217244. 2022 Jun 17.
Mahoney R, Hotez PJ, Bottazzi ME. Global regulatory reforms to promote equitable vaccine access in the next pandemic. PLOS Glob Public Health. 2023 Oct 18;3(10):e0002482. doi: 10.1371/journal.pgph.0002482. PMID: 37851688; PMCID: PMC10584090.
Kumar N, Darshan M, Islam F. Ensuring global health: a comprehensive review of vaccine regulation with a focus on the Indian perspective. International Journal of Community Medicine and Public Health. 2024 Feb;11[2]:989.
Tizard, Ian R.. “Production, assessment, and regulation of vaccines.” (2021).
Baylor NW. The Regulatory Evaluation of Vaccines for Human Use. Methods Mol Biol. 2016;1404:773-787. doi: 10.1007/978-1-4939-3389-1_51. PMID: 27076337.
Gorenkov DV, Komarovskaya EI, Soldatov AA, Avdeeva ZhI BV. Current regulatory requirements for non-clinical evaluation of prophylactic vaccines. Biological Products. Prevention, Diagnosis, Treatment. 2023;23(1):7-25.
Souto EB, Blanco-Llamero C, Krambeck K, Kiran NS, Yashaswini C, Postwala H, Severino P, Priefer R, Prajapati BG, Maheshwari R. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives. Acta Biomater. 2024 May;180:1-17. doi: 10.1016/j.actbio.2024.04.010. Epub 2024 Apr 10. PMID: 38604468.
Särnefält A, Eardley-Patel R, Magini D, Sonje V, Guzzi A, Hesselink R, Scotney M, Lazdins A, Chambard V, Vinnemeier C, Kromann I. A Strategic Guide to Improve and De-Risk Vaccine Development: CEPI's CMC Framework. PDA J Pharm Sci Technol. 2024 Oct 22;78(5):613-623. doi: 10.5731/pdajpst.2023.012912. PMID: 39054065.
Narasimhan J, Maanvizhi S. Regulatory approval pathway for COVID-19 vaccine in USA, Europe and India. Ann Med Surg (Lond). 2023 Mar 2;85(4):860-867. doi: 10.1097/MS9.0000000000000000. PMID: 37113820; PMCID: PMC10129106.
Gestakovska A, Moskova B, Sterjev Z, Grozdanova A, Suturkova L, Nestorovska AK, Naumovska Z. The legal and regulatory framework for vaccine pharmacovigilance.
Pathak D, Philo Magdalene A. COVID-19 Vaccine Development and Administration in India. InHealth Dimensions of COVID-19 in India and Beyond 2022 Apr 9 (pp. 129-154). Singapore: Springer Nature Singapore.
PONNAPALLI, RAMYA & DIVYA, MANTENA & Raju, K. & Nori, Lakshmi. (2023). REGULATORY FRAMEWORK: VACCINE DEVELOPMENT IN US, INDIA AND EU. International Journal of Applied Pharmaceutics. 63-71. 10.22159/ijap.2023v15i2.46723.
Gogtay NJ, Dhingra MS, Yadav A, Chandwani H. Vaccine policy, regulations and safety in India. International Journal of Risk & Safety in Medicine. 2009 Jan 1;21(1-2):23-30.
Dinda AK, Tripathi SK, John B. Revisiting regulatory framework in India for accelerated vaccine development in pandemics with an evidence-based fast-tracking strategy. Indian J Med Res. 2020 Jul & Aug;152(1 & 2):156-163. doi: 10.4103/ijmr.IJMR_3640_20. PMID: 32952146; PMCID: PMC7853266.
Grundy J. Country-level governance of global health initiatives: an evaluation of immunization coordination mechanisms in five countries of Asia. Health Policy Plan. 2010 May;25(3):186-96. doi: 10.1093/heapol/czp047. Epub 2009 Nov 19. PMID: 19926659.
Shinde AA, Gurav AS, Chaudhari BP, Redasani VK. A Review on Pharmaceutical Regulatory Authority of India, USA, UK, Australia. Asian Journal of Research in Pharmaceutical Science. 2024 Sep 1;14(3).
Gowthami KR, Balamuralidhara V., Maanvizhi S, Deeksha KS, Bairi MU. Regulatory Requirements and Approval Process for Medical Devices in Japan, Australia and Brazil. ACMMR-V8 [Internet]. 2023 Dec. 15 [cited 2024 Dec. 26];:127-53. Available from: https://stm.bookpi.org/ACMMR-V8/article/view/12792
Khadem Broojerdi A, Alfonso C, Ostad Ali Dehaghi R, Refaat M, Sillo HB. Worldwide Assessment of Low- and Middle-Income Countries' Regulatory Preparedness to Approve Medical Products During Public Health Emergencies. Front Med (Lausanne). 2021 Aug 13;8:722872. doi: 10.3389/fmed.2021.722872. PMID: 34485350; PMCID: PMC8414408.
Nagai S, Ozawa K. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products. Curr Gene Ther. 2017;17(1):17-28. doi: 10.2174/1566523217666170406123231. PMID: 28382858.
T R P, Kumar S, R K. A Comparative Analysis of the Regulatory Framework and Collaborative Environment for Pediatric Medical Device Development in Japan and the United States: Identifying Challenges, Support Mechanisms, and Emerging Opportunities. Cureus. 2024 Sep 3;16(9):e68583. doi: 10.7759/cureus.68583. PMID: 39371858; PMCID: PMC11452317.
Jones PG, Cowan G, Gravendyck M, Nagata T, Robinson S, Waits M. Regulatory requirements for vaccine authorisation. Rev Sci Tech. 2007 Aug;26[2]:379-93. PMID: 17892159.
Lodha S, Patel H, Joshi S, Kalyankar G, Mishra A. Regulatory requirements of regulated market. InRegulatory Affairs in the Pharmaceutical Industry 2022 Jan 1 (pp. 113-161). Academic Press.
Hock SC, Pheh A, Sachdeva V, Wah CL. Challenges in the manufacture, storage, distribution and regulation of traditional and novel vaccines. GaBI Journal. 2022;11(1):13-24.
Moore HC, Cannon JW, Kaslow DC, Lamagni T, Bowen AC, Miller KM, Cherian T, Carapetis J, Van Beneden C. A Systematic Framework for Prioritizing Burden of Disease Data Required for Vaccine Development and Implementation: The Case for Group A Streptococcal Diseases. Clin Infect Dis. 2022 Sep 30;75(7):1245-1254. doi: 10.1093/cid/ciac291. PMID: 35438130; PMCID: PMC9525082.
Nishioka Sde A. Cooperation between regulatory authorities from developing countries in the evaluation of vaccine clinical trials. Cad Saude Publica. 2008 Sep;24(9):2191-2. doi: 10.1590/s0102-311x2008000900026. PMID: 18813696.
Radhakrishna SD, Shriram RG, Khaleeli S, Dawar P, Kottayi MC, Dubey A. Comparison and Compilation of the vaccine Approval process of the United States of America and the European union: a Road Map for the emerging and developing countries in COVID-19 crisis. Indian J of Pharmaceutical Education and Research. 2021 Apr 1;55(2s):s353-63.
Jose J, Pai S. Comparison of regulatory framework of clinical trial with genetically modified organism-containing vaccines in the Europe, Australia, and Switzerland. Clin Exp Vaccine Res. 2021 May;10[2]:93-105. doi: 10.7774/cevr.2021.10.2.93. Epub 2021 May 31. PMID: 34222122; PMCID: PMC8217574.
Ingle D, Bhavsar R, Pawar J, Patil A, Nerkar P. Overview oi vaccine regulations in european union and Japan. International Journal Of Drug Regulatory Affairs. 2022;10(1):14-22.
Sutkowski EM, Gruber MF. Regulatory considerations in the nonclinical safety assessment of adjuvanted preventive vaccines. InImmunopotentiators in Modern Vaccines 2006 Jan 1 (pp. 343-359). Academic Press.
Ujiie M. Establishment of an emergency regulatory approval system in Japan in response to the COVID-19 pandemic and challenges in developing domestically produced vaccines. Glob Health Med. 2022 Apr 30;4[2]:144-145. doi: 10.35772/ghm.2022.01023. PMID: 35586772; PMCID: PMC9066468.
Kondo K, Taguchi C. Japanese Regulatory Framework and Approach for Genome-edited Foods Based on Latest Scientific Findings. Food Saf (Tokyo). 2022 Dec 23;10(4):113-128. doi: 10.14252/foodsafetyfscj.D-21-00016. PMID: 36619008; PMCID: PMC9789915.
Honig P, Zhang L. Regulation and Innovation: Role of Regulatory Science in Facilitating Pharmaceutical Innovation. Clin Pharmacol Ther. 2019 Apr;105(4):778-781. doi: 10.1002/cpt.1367. PMID: 30883715.
Dellepiane N, Akanmori BD, Gairola S, Jadhav SS, Parker C, Rodriguez C, Srivastava S. Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries. Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S428-33. doi: 10.1093/cid/civ491. PMID: 26553671; PMCID: PMC4639481.
Milstien J, Belgharbi L. Regulatory pathways for vaccines for developing countries. Bull World Health Organ. 2004 Feb;82[2]:128-33. Epub 2004 Mar 16. Erratum in: Bull World Health Organ. 2004 Nov;82(11):881. PMID: 15042235; PMCID: PMC2585911.
Cox MM, Onraedt A. Innovations in vaccine development: can regulatory authorities keep up? Expert Rev Vaccines. 2012 Oct;11(10):1171-3. doi: 10.1586/erv.12.96. PMID: 23176649.
Jones C. Glycoconjugate Vaccines: The Regulatory Framework. Methods Mol Biol. 2015;1331:229-51. doi: 10.1007/978-1-4939-2874-3_14. PMID: 26169744.
Dellepiane N, Pagliusi S, Akut P, Comellas S, De Clercq N, Ghadge S, Gastineau T, McGoldrick M, Nurnaeni I, Scheppler L; Regulatory Experts Working Group. Alignment in post-approval changes (PAC) guidelines in emerging countries may increase timely access to vaccines: An illustrative assessment by manufacturers. Vaccine X. 2020 Aug 25;6:100075. doi: 10.1016/j.jvacx.2020.100075. PMID: 32995745; PMCID: PMC7516132.
Gronvall GK, Borio LL. Removing barriers to global pandemic influenza vaccination. Biosecur Bioterror. 2006;4[2]:168-75. doi: 10.1089/bsp.2006.4.168. PMID: 16792484.
Hausdorff WP, Madhi SA, Kang G, Kaboré L, Tufet Bayona M, Giersing BK. Facilitating the development of urgently required combination vaccines. Lancet Glob Health. 2024 Jun;12(6):e1059-e1067. doi: 10.1016/S2214-109X(24)00092-5. Epub 2024 Apr 15. Erratum in: Lancet Glob Health. 2024 Apr 25:S2214-109X(24)00184-0. doi: 10.1016/S2214-109X(24)00184-0. PMID: 38636529; PMCID: PMC11099297.
Lalani B, Sobti S. Adopting a logical framework model to help achieve a balanced and healthy vaccine R&D portfolio. Wellcome Open Res. 2019 Jul 1;4:64. doi: 10.12688/wellcomeopenres.15168.2. PMID: 31346552; PMCID: PMC6625608.
Marandi V, Tabatabaeian SH, Jafari P, Azarnoosh M. Challenge-based approaches for policy-making in vaccine development and production.
Patel M, Miller MA. Impact of regulatory science on global public health. Kaohsiung J Med Sci. 2012 Jul;28(7 Suppl):S5-9. doi: 10.1016/j.kjms.2012.05.003. Epub 2012 Jul 10. PMID: 22871603.
Breckenridge A, Feldschreiber P, Gregor S, Raine J, Mulcahy LA. Evolution of regulatory frameworks. Nat Rev Drug Discov. 2011 Jan;10(1):3-4. doi: 10.1038/nrd3348. PMID: 21193854.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
